stockrow
Friday 6 November 2026
Export OWLT’s income statement to Excel — free account
Owlet, Inc.
OWLT Healthcare Medical Devices
Owlet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $105.7 million, up 35.4% from fiscal 2024.
- Revenue
- +29.9%
- EPS
- +97.9%
- Free cash flow
- +55.7%
- Total debt
- −16.9%
Quarter to June 2026, against a year earlier
4.19
0.05
−1.18%
Follow OWLT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 75 | 76 | 69 | 54 | 78 | 106 | 115 | +7.0% | 120 | 144 | 186 | +20.7% | |
| Gross margin, % | — | — | — | — | 47.58 | 46.23 | 33.69 | 41.82 | 50.36 | 50.64 | 54.75 | +3.1 pt | ||||||
| EBT | — | — | — | — | (11) | (72) | (79) | (33) | (12) | (40) | (9) | +30.4% | ||||||
| EBT margin, % | — | — | — | — | (13.93) | (94.50) | (114.60) | (60.90) | (15.99) | (37.51) | (8.05) | (23.6) pt | ||||||
| Net income | — | 0 | — | — | (11) | (72) | (79) | (33) | (13) | (40) | (10) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 48.10 | 16.80 | 8.70 | 6.53 | 7.13 | 5.84 | 4.03 | (34.4%) | |||||
| Earnings | — | — | — | — | (6.71) | (15.83) | (9.94) | (4.53) | (1.57) | (2.31) | (0.42) | (19.2%) | ||||||
| Cash flow | — | — | — | — | (0.08) | (8.99) | (10.24) | (2.84) | (1.02) | (0.60) | (0.27) | +48.6% | ||||||
| Capex | — | — | — | — | (0.67) | (0.45) | (0.20) | (0.01) | (0.07) | (0.05) | (0.07) | (40.1%) | ||||||
| Free cash flow | — | — | — | — | (0.76) | (9.43) | (10.43) | (2.85) | (1.09) | (0.65) | (0.35) | (3.0%) | ||||||
| Book value | — | — | — | — | (13.28) | 12.23 | (1.34) | (3.59) | (2.77) | 1.05 | 0.81 | n/m | ||||||
| Shares, m | — | — | — | — | 2 | 5 | 8 | 8 | 11 | 18 | 23 | +63.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 2.22 | 0.92 | 0.88 | 0.62 | 2.77 | 1.05 | 1.2 | ||||||
| P/B | — | — | — | — | 20.50 | 3.06 | 0.00 | 0.00 | 0.00 | 15.38 | 5.21 | 6.5 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 1.19 | 1.00 | 0.87 | 0.51 | 2.51 | 0.90 | 1.0 | ||||||
| EV/FCF | — | — | — | — | 0.00 | (2.12) | (0.84) | (1.98) | (3.32) | (22.58) | (10.45) | (5.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (41) | (81) | (24) | (11) | (11) | (8) | +142.4% | |||||
| Capex | — | — | — | — | (1) | (2) | (2) | 0 | (1) | (1) | (2) | (2.2%) | ||||||
| Free cash flow | — | — | — | — | (1) | (43) | (83) | (24) | (12) | (12) | (10) | +58.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (10) | 67 | (15) | (5) | 10 | 38 | 34 | n/m | |||||
| Net debt | — | — | — | — | 5 | (79) | 4 | (1) | (9) | (28) | (19) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | (21) | 55 | (11) | (30) | (30) | 19 | 23 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (52.45) | (79.60) | (80.08) | (73.35) | (36.79) | (61.96) | (15.60) | (9.5) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (131.04) | 0.0 pt | ||||||
| ROE | — | — | — | — | (8.25) | 1,118.80 | (356.12) | 155.68 | 51.18 | 781.68 | 68.03 | +789.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 3 | 200 | 106 | 76 | 85 | 114 | — | +107.0% | |||||
| Revenue/emp, $m | — | — | — | — | 25.13 | 0.38 | 0.65 | 0.71 | 0.92 | 0.93 | — | (48.3%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Owlet, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INGN Inogen, Inc | $179.7M | — (loss-making) | — (loss-making) | +3.04% (above 0%: growing) | n/m | −51.15% (below 0%: shrinking) | 45.51% | (5.36%) | Compare |
| MXCT MaxCyte, Inc. | $135.2M | — (loss-making) | — (loss-making) | −14.53% (below 0%: shrinking) | n/m | +54.74% (above 0%: growing) | 76.96% | (140.72%) | Compare |
| QTRX Quanterix Corporation | $130.5M | — (loss-making) | — (loss-making) | +34.44% (above 0%: growing) | n/m | +18.92% (above 0%: growing) | 38.52% | (150.22%) | Compare |
| APYX Apyx Medical Corporation | $128.9M | — (loss-making) | — (loss-making) | +8.95% (above 0%: growing) | n/m | +53.17% (above 0%: growing) | 64.16% | (4.07%) | Compare |
| OWLT Owlet, Inc. | $123.9M | — (loss-making) | — (loss-making) | +29.94% (above 0%: growing) | n/m | +55.74% (above 0%: growing) | 64.44% | 5.14% | |
| LUNG Pulmonx Corporation | $111.5M | — (loss-making) | — (loss-making) | +6.20% (above 0%: growing) | n/m | +61.33% (above 0%: growing) | 76.19% | (32.80%) | Compare |
| ZOMDF Zomedica Corp. | $95.4M | — (loss-making) | — (loss-making) | +22.29% (above 0%: growing) | n/m | +32.51% (above 0%: growing) | 61.06% | (34.60%) | Compare |
| CATX Perspective Therapeutics, Inc. | $90.0M | — (loss-making) | — (loss-making) | −72.07% (below 0%: shrinking) | n/m | −66.09% (below 0%: shrinking) | 100.00% | (36,120.99%) | Compare |
| LUCD Lucid Diagnostics Inc. | $79.3M | — (loss-making) | — (loss-making) | +26.74% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 1.97% | (868.45%) | Compare |
| Median of peers | $120.2M | — | — | +7.58% | — | +25.72% | 62.61% | (87.66%) |
Pay and ownership Proxy statement filed 30 June 2026
Ownership
Directors and executive officers, together
35.22% of the votes
Entities affiliated with Eclipse
30.59% of the votes
Lior Susan
30.59% of the votes
Trilogy Equity Partners, LLC
6.41% of the votes
AWM Investment Company, Inc.
5.51% of the votes
John Stanton and Theresa Gillespie
1.97% of the votes
The Melton
1.45% of the votes
Litespeed Capital, LLC
0.97% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement